Promiliad Biopharma
Promiliad Biopharma is an innovative pharmaceutical company specializing in antibiotic development, natural product research, and in vitro evaluation techniques. They focus on creating novel antibiotics, reducing animal testing through proprietary technologies, and addressing unmet medical needs with strategic partnerships and rigorous research.
Industries
Nr. of Employees
small (1-50)
Promiliad Biopharma
950 West Fork Petty Creek Road, Alberton, MT 59820-9437
Products
Natural product fragment libraries
Collections of purified natural product fragments and synthetically expanded analogs designed for high‑throughput screening against bacterial targets.
In‑vitro concentration‑time profile simulation platform (service/product)
Laboratory platform and service to simulate drug concentration–time profiles in bacterial cultures for PK/PD experiments and to reduce reliance on animal models.
Novel antibiotic lead compounds from natural product‑like libraries
Discovery and early‑stage development of novel structural classes of antibiotics derived from combinatorial biosynthetic‑synthetic libraries, intended for progression toward IND.
Natural product fragment libraries
Collections of purified natural product fragments and synthetically expanded analogs designed for high‑throughput screening against bacterial targets.
In‑vitro concentration‑time profile simulation platform (service/product)
Laboratory platform and service to simulate drug concentration–time profiles in bacterial cultures for PK/PD experiments and to reduce reliance on animal models.
Novel antibiotic lead compounds from natural product‑like libraries
Discovery and early‑stage development of novel structural classes of antibiotics derived from combinatorial biosynthetic‑synthetic libraries, intended for progression toward IND.
Services
Contract laboratory services including in‑vitro antibacterial potency testing (MIC), mammalian cell toxicity, AMES mutagenicity, microsomal stability, controlled in‑vitro PK/PD profiling, resistance profiling, and in‑vivo MTD and PK in rodents.
Contract laboratory services including in‑vitro antibacterial potency testing (MIC), mammalian cell toxicity, AMES mutagenicity, microsomal stability, controlled in‑vitro PK/PD profiling, resistance profiling, and in‑vivo MTD and PK in rodents.
Expertise Areas
- Preclinical antibiotic development
- Natural product discovery and library design
- PK/PD modeling and in‑vitro pharmacokinetic simulation
- Microbiological assay development and ISO analytical testing
Key Technologies
- In‑vitro pharmacokinetic simulation devices
- Minimum inhibitory concentration (MIC) assays
- AMES mutagenicity assay
- Liver microsomal stability assays
News & Updates
Promiliad Biopharma received a $1,496,891 award from NIH to develop a new structural class of antibiotic, aiming to improve potency and selectivity of lead compounds derived from natural products.
Received a significant grant to develop novel antibiotics from natural products, advancing towards IND application.
Promiliad Biopharma received a $1,496,891 award from NIH to develop a new structural class of antibiotic, aiming to improve potency and selectivity of lead compounds derived from natural products.
Received a significant grant to develop novel antibiotics from natural products, advancing towards IND application.